Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, and ABL Bio Inc. (“ABL”, KOSDAQ: 298380), a Korean clinical-stage biotechnology company developing novel therapeutics in oncology and CNS diseases, today announced a collaboration to develop new bispecific antibody-drug conjugates (bsADCs).
Biocytogen’s RenLite® mice platform can produce fully human antibodies with diverse epitopes and high affinity. This platform is notable for its ability to generate antibodies in a common light chain format, offering a distinctive combination of design flexibility, simplified manufacturing processes, and optimal developability for bsADC development. Based on this platform, both companies will be able to discuss expanding their collaboration for various types of ADC development.
Dr. Yuelei Shen, President and CEO of Biocytogen, said, “We are very pleased to collaborate with ABL, a company that possesses advanced platforms for cancer immunotherapy and treatments against CNS diseases. ABL’s consistent success in advancing its pipeline strongly showcases its expertise and capabilities in regulatory, clinical development, and business development activities. BsADC drugs derived from our RenLite® mice platform have shown preferable potency in various tumor models, while also exhibiting good safety profiles. We believe our fully human bsADC platform technology, which features increased tumor selectivity, target synergized internalization, and convenient CMC development, will complement ABL's capabilities effectively. Together, we aim to expedite the development of innovative bsADC therapies.”
Sang Hoon Lee, CEO of ABL, said, “We are excited to establish this partnership with Biocytogen for bsADCs. This collaboration is one of the stepping stones for getting down to developing bsADCs. We look forward to a productive collaboration, and firmly believe that this partnership will contribute towards creating a distinctive pipeline, ultimately leading to novel therapies that improve the quality of life for patients.”
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMabTM/RenLite®/RenNano®/RenTCR-mimicTM) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologicsTM, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of June 30, 2023, 50 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 42 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMiceTM, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.
About ABL Bio
ABL Bio Inc. (KOSDAQ: 298380) is a clinical-stage biotechnology company developing antibody therapeutics for immune-oncology and neurodegenerative diseases. With internal R&D and global partnerships, ABL has developed multiple BsAb platforms, such as ‘Grabody-T,’ ‘Grabody-B’ and built an innovative pipeline of multiple clinical and pre-clinical stage drug candidates. In the oncology area, we have developed Grabody-T, a modular 4-1BB engaging platform that has demonstrated superior efficacy and safety. In the neurodegenerative disorder space, we have developed Grabody-B, which is designed to maximize blood-brain barrier (BBB) penetration. Grabody-B is applicable to various CNS targets across a plethora of neurological disorders, potentially providing a breakthrough to address the high unmet medical needs in neurodegeneration. For more information, please visit www.ablbio.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240325027750/en/
Contact information
Biocytogen
Antibody assets and platforms: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Celonis Named a Leader in Process Intelligence Software12.8.2025 19:18:00 EEST | Press release
Celonis, a global leader in Process Mining, today announced it has been named a Leader in The Forrester Wave™: Process Intelligence Software, Q3 2025. According to the report, “Celonis is best suited to clients looking for a sophisticated platform that supports enterprise-wide process intelligence and control to transform operations.” Forrester also cited Celonis’ trailblazing role in the category, noting its early adoption of graph databases, an additional object-centric view of process performance, and an extended marketplace of partner-built solutions. “We are honored to be named a Leader in The Forrester Wave: Process Intelligence. This recognition is only possible because of the dedication and commitment of our customers, partners and Celonauts,” said Carsten Thoma, President and Board Director, Celonis. “Enterprise AI is set to reinvent operations. To deliver on its full potential, AI needs to understand how each business runs and how to make it run better. Our Process Intelligen
Empowering Developers to Monetize Anywhere: Xsolla Expands Platform Support for Cross-Platform Direct-to-Consumer Commerce12.8.2025 19:00:00 EEST | Press release
Xsolla, a global commerce company helping developers launch, grow, and monetize their games, announces today a major expansion of its platform support capabilities, reinforcing its position as the premier provider of cross-platform monetization solutions for developers. With the latest SDKs for Windows Stores and the Epic Games Store, a new strategic partnership with Pley, and the launch of the Xsolla Discord Bot, developers can now implement secure, streamlined commerce across PC, mobile, web, and community platforms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250812673202/en/ (Graphic: Xsolla) Key Platform Expansions Now Available to Developers: SDK for Windows stores PC developers can access flexible monetization tools via Xsolla SDK for Windows Stores, offering seamless checkout flows and cross-platform SKU synchronization for multiplatform titles available on Windows across a variety of game stores. Setup is streaml
Andersen Consulting Expands Digital Transformation Solutions with Future Processing12.8.2025 16:30:00 EEST | Press release
Andersen Consulting announces a Collaboration Agreement with Future Processing, a technology and software consultancy, strengthening the organization’s ability to deliver end-to-end digital solutions. Founded in 2000 in Poland, Future Processing has been successfully delivering advanced IT projects for clients worldwide for over two decades. The company provides a full spectrum of services based on extensive technological expertise and advisory capabilities—from consulting and digital product strategy to custom software development, cloud, data, AI, machine learning, and cybersecurity solutions. Their expertise enables clients to adopt AI, migrate and integrate systems, modernize and scale cloud infrastructure, optimize and manage IT operations, and execute performance-led engineering initiatives. “Through our collaboration with Andersen Consulting, we advance our mission to deliver technology solutions at scale,” said Michał Sztanga, managing director of Future Processing. “Together,
Unity Game Developers Can Now Enable Direct-to-Consumer Monetization With Xsolla’s New SDK12.8.2025 16:00:00 EEST | Press release
Xsolla, a global commerce company helping developers launch, grow, and monetize their games, today announces the launch of an SDK for Unity that expands monetization capabilities for developers using the Unity engine. This new SDK is a part of Xsolla’s continued mission to unlock direct-to-consumer revenue opportunities across all platforms - mobile, PC, and the web - without complex backend work. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250812923531/en/ (Graphic: Xsolla) Whether building a mobile-first title, a PC game, or a browser-based game, Unity developers can now integrate payments, enable in-game purchases, and create custom storefronts without relying on closed platforms. With a fast time-to-market, developers can start selling directly to their players and retain more of their revenue from day one, while maintaining full ownership of the checkout experience, player data, and monetization strategy. Key benefit
Gogo Galileo HDX Connectivity Option Now Available on Cessna Citation CJ4 Gen312.8.2025 16:00:00 EEST | Press release
Customers who will be taking delivery of the Cessna Citation CJ4 Gen3 business jet now have the option to include the Gogo Galileo HDX connectivity solution installed on their aircraft. By integrating Gogo Galileo HDX, customers can benefit from an additional global connectivity solution that delivers exceptional performance. Announced in October 2024, the CJ4 Gen3 is expected to enter into service in 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250812553974/en/ Gogo Galileo HDX connectivity option now available on Cessna Citation CJ4 Gen3 (Photo Credit: Textron Aviation). The Cessna Citation CJ4 Gen3 is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. “Cessna Citation business jets are known for their luxury and productivity,” said Lannie O’Bannion, senior vice president, Sales & Marketing. “Whether for work or entertainment, this robust solution ensures customers’ in-flight exp
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom